Scientific article
English

Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial

Published in

Lancet, vol. 379, no. 9823, p. 1301-1309

Publication date

2012

Abstract

Hepatic veno-occlusive disease is a leading cause of morbidity and mortality after haemopoietic stem-cell transplantation (HSCT). We aimed to assess whether defibrotide can reduce the incidence of veno-occlusive disease in this setting.

Keywords

  • Adolescent
  • Bilirubin/blood
  • Child
  • Child, Preschool
  • Female
  • Fibrinolytic Agents/therapeutic use
  • Graft vs Host Disease/epidemiology
  • Hematopoietic Stem Cell Transplantation/adverse effects
  • Hepatic Veno-Occlusive Disease/drug therapy/epidemiology/prevention & control
  • Humans
  • Incidence
  • Infant
  • Infusions, Intravenous
  • Male
  • Multiple Organ Failure/epidemiology
  • Polydeoxyribonucleotides/therapeutic use
  • Renal Insufficiency/epidemiology

Citation (ISO format)

CORBACIOGLU, Selim et al. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. In: Lancet, 2012, vol. 379, n° 9823, p. 1301–1309. doi: 10.1016/S0140-6736(11)61938-7

Main files (1)

Article (Published version)

Identifiers

Journal ISSN

0140-6736
701views
0downloads

Technical informations

Creation

10/10/2013 14:46:00

First validation

10/10/2013 14:46:00

Update

14/03/2023 20:38:52

Status update

14/03/2023 20:38:50

Last indexation

30/10/2024 15:05:21
All rights reserved by Archive ouverte UNIGE and the University of Geneva
OpenAIRE Indexed & Validated